Instituto RosenbuschBUE:ROSE 39 Market Cap is ARS6,942 Mil as of Jul. 02, 2026. GuruFocus rates BUE:ROSE with a GF Score™ of 39/100 and a GF Value™ of ARS61.84 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Instituto Rosenbusch ranks worse than 90.71% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Instituto Rosenbusch's share price for the quarter that ended in Dec. 2025 was ARS240.5. Instituto Rosenbusch's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 43 Mil. Therefore, Instituto Rosenbusch's market cap for the quarter that ended in Dec. 2025 was ARS10,243 Mil.
Instituto Rosenbusch's quarterly market cap
declined
from Jun. 2025 (ARS7,538 Mil) to Sep. 2025 (ARS5,664 Mil) but then
increased
from Sep. 2025 (ARS5,664 Mil) to Dec. 2025 (ARS10,243 Mil).
Instituto Rosenbusch's annual market cap
increased
from Dec. 2023 (ARS2,726 Mil) to Dec. 2024 (ARS5,196 Mil) and
increased
from Dec. 2024 (ARS5,196 Mil) to Dec. 2025 (ARS10,243 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Instituto Rosenbusch's Enterprise Value for Today is ARS7,954 Mil.
Instituto Rosenbusch (BUE:ROSE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Instituto Rosenbusch Market Cap Related Terms
Instituto Rosenbusch Market Cap Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:ROSE vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Market Cap distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Instituto Rosenbusch's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a Market Cap of ARS6,942 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Instituto Rosenbusch and its competitors. According to the industry distribution chart, Instituto Rosenbusch ranks #928 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 90.7%.
Is Instituto Rosenbusch's Market Cap too high?
Instituto Rosenbusch's current Market Cap is ARS6,942 Mil. Based on the distribution chart, Instituto Rosenbusch ranks #928 out of 1023 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #928 out of 1023 companies for Market Cap. This places Instituto Rosenbusch in the lower half of its industry. The industry median Market Cap is 213.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.88, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current Market Cap is ARS6,942 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.84, compared to a current price of ARS163.00 — trading 163.6% above its estimated fair value. The current Market Cap is ARS6,942 Mil. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Market Cap is ARS6,942 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS163.00 is trading 163.6% above its estimated GF Value™ of ARS61.84.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
Market Cap: ARS6,942 Mil
GF Value™: ARS61.84 vs. price of ARS163.00 (163.6% above fair value)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score
Get the complete analysis for BUE:ROSE
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
